Literature DB >> 2496196

A marked rise in 5-S-cysteinyl-dopamine levels in guinea-pig striatum following reserpine treatment.

B Fornstedt1, A Carlsson.   

Abstract

Reserpine administration (5 mg/kg, i.p.) to guinea pigs resulted in marked and long lasting dopamine (DA) depletion and a rapid, short lasting, increase of 3,4-dihydroxyphenylacetic acid (DOPAC) in the striatum. A marked and sustained increase of the level of 5-S-cysteinyl-dopamine, which is an adduct presumably formed following autoxidation of DA, started 3-4 h following the DA and DOPAC changes. Only small changes in the levels of the 5-S-cysteinyl adducts of DOPAC and 3,4-dihydroxyphenylalanine (DOPA) were found.

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2496196     DOI： 10.1007/bf01578755

Source DB:  PubMed          Journal:  J Neural Transm            Impact factor:   3.575


  12 in total

1.  A study of the factors affecting the aluminum oxide-trihydroxyindole procedure for the analysis of catecholamines.

Authors:  A H ANTON; D F SAYRE
Journal:  J Pharmacol Exp Ther       Date:  1962-12       Impact factor: 4.030

2.  Irreversible binding of DOPA and dopamine metabolites to protein by rat liver microsomes.

Authors:  M Scheulen; P Wollenberg; H M Bolt; H Kappus; H Remmer
Journal:  Biochem Biophys Res Commun       Date:  1975-10-27       Impact factor: 3.575

3.  L-dopa: selective toxicity for melanoma cells in vitro.

Authors:  M M Wick; L Byers; E Frei
Journal:  Science       Date:  1977-07-29       Impact factor: 47.728

4.  Occurrence and distribution of 5-S-cysteinyl derivatives of dopamine, dopa and dopac in the brains of eight mammalian species.

Authors:  B Fornstedt; E Rosengren; A Carlsson
Journal:  Neuropharmacology       Date:  1986-04       Impact factor: 5.250

5.  Autoxidation versus covalent binding of quinones as the mechanism of toxicity of dopamine, 6-hydroxydopamine, and related compounds toward C1300 neuroblastoma cells in vitro.

Authors:  D G Graham; S M Tiffany; W R Bell; W F Gutknecht
Journal:  Mol Pharmacol       Date:  1978-07       Impact factor: 4.436

6.  Brain peroxidase and catalase in Parkinson disease.

Authors:  L M Ambani; M H Van Woert; S Murphy
Journal:  Arch Neurol       Date:  1975-02

7.  Genetic toxicity of dopamine.

Authors:  P Moldéus; M Nordenskjöld; G Bolcsfoldi; A Eiche; U Haglund; B Lambert
Journal:  Mutat Res       Date:  1983-10       Impact factor: 2.433

8.  Levodopa and dopamine analogs as DNA polymerase inhibitors and antitumor agents in human melanoma.

Authors:  M M Wick
Journal:  Cancer Res       Date:  1980-05       Impact factor: 12.701

9.  Diastereomers of 5-S-cysteinyldopa.

Authors:  G Agrup; L E Edholm; H Rorsman; E Rosengren
Journal:  Acta Derm Venereol       Date:  1983       Impact factor: 4.437

10.  Detection of 5-S-cysteinyldopamine in human brain.

Authors:  E Rosengren; E Linder-Eliasson; A Carlsson
Journal:  J Neural Transm       Date:  1985       Impact factor: 3.575
View more
  17 in total

1.  Synergism between methamphetamine and the neuropeptide substance P on the production of nitric oxide in the striatum of mice.

Authors:  Jing Wang; Jesus A Angulo
Journal:  Brain Res       Date:  2010-11-11       Impact factor: 3.252

2.  Disruption of dopamine transport by DDT and its metabolites.

Authors:  Jaime M Hatcher; Kristin C Delea; Jason R Richardson; Kurt D Pennell; Gary W Miller
Journal:  Neurotoxicology       Date:  2008-04-29       Impact factor: 4.294

3.  Elevated 5-S-cysteinyldopamine/homovanillic acid ratio and reduced homovanillic acid in cerebrospinal fluid: possible markers for and potential insights into the pathoetiology of Parkinson's disease.

Authors:  F C Cheng; J S Kuo; L G Chia; G Dryhurst
Journal:  J Neural Transm (Vienna)       Date:  1996       Impact factor: 3.575

4.  The effects of GBR 12909, a dopamine re-uptake inhibitor, on monoaminergic neurotransmission in rat striatum, limbic forebrain, cortical hemispheres and substantia nigra.

Authors:  H Nissbrandt; G Engberg; E Pileblad
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1991-07       Impact factor: 3.000

5.  Effect of L-dopa, oxyferriscorbone and ferrous iron on in vivo lipid peroxidation.

Authors:  P Dostert; M S Benedetti; E Frigerio
Journal:  J Neural Transm Gen Sect       Date:  1991

6.  Increased methamphetamine neurotoxicity in heterozygous vesicular monoamine transporter 2 knock-out mice.

Authors:  F Fumagalli; R R Gainetdinov; Y M Wang; K J Valenzano; G W Miller; M G Caron
Journal:  J Neurosci       Date:  1999-04-01       Impact factor: 6.167

7.  Methamphetamine-induced degeneration of dopaminergic neurons involves autophagy and upregulation of dopamine synthesis.

Authors:  Kristin E Larsen; Edward A Fon; Teresa G Hastings; Robert H Edwards; David Sulzer
Journal:  J Neurosci       Date:  2002-10-15       Impact factor: 6.167

Review 8.  The catecholaldehyde hypothesis: where MAO fits in.

Authors:  David S Goldstein
Journal:  J Neural Transm (Vienna)       Date:  2019-12-05       Impact factor: 3.575

9.  Increased expression of the dopamine transporter leads to loss of dopamine neurons, oxidative stress and l-DOPA reversible motor deficits.

Authors:  S T Masoud; L M Vecchio; Y Bergeron; M M Hossain; L T Nguyen; M K Bermejo; B Kile; T D Sotnikova; W B Siesser; R R Gainetdinov; R M Wightman; M G Caron; J R Richardson; G W Miller; A J Ramsey; M Cyr; A Salahpour
Journal:  Neurobiol Dis       Date:  2014-10-30       Impact factor: 5.996

10.  Dopamine disposition in the presynaptic process regulates the severity of methamphetamine-induced neurotoxicity.

Authors:  Donald M Kuhn; Dina M Francescutti-Verbeem; David M Thomas
Journal:  Ann N Y Acad Sci       Date:  2008-10       Impact factor: 5.691
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.